Cargando…
Modeling breast cancer proliferation, drug synergies, and alternating therapies
Estrogen receptor positive (ER+) breast cancer is responsive to a number of targeted therapies used clinically. Unfortunately, the continuous application of targeted therapy often results in resistance, driving the consideration of combination and alternating therapies. Toward this end, we developed...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206440/ https://www.ncbi.nlm.nih.gov/pubmed/37234088 http://dx.doi.org/10.1016/j.isci.2023.106714 |